Several arenaviruses, chiefly Lassa virus (LASV), cause hemorrhagic fever (HF) 22 disease in humans and pose a significant public health concern in their endemic regions. 23
INTRODUCTION 35
Several arenaviruses cause hemorrhagic fever (HF) disease in humans. Thus, Lassa 36 virus (LASV) and Junin virus (JUNV) are the causative agents of Lassa fever (LF) and 37
Argentine HF disease, respectively, which represent significant public health problems 38 within their endemic geographic regions of West Africa (LASV) and Argentina (JUNV). In 39 addition, evidence indicates that the globally distributed prototypic arenavirus LCMV is a 40 neglected human pathogen of clinical significance in congenital viral infections (3, 15, 24) . 41
Moreover, LCMV infection of immunosuppressed individuals can result in severe disease 42 and death (13, 30) . Public health concerns about arenavirus infections are aggravated by 43 lack of FDA licensed vaccines and limited existing therapeutic options. The only arenavirus 44 vaccine tested in humans is Candid 1, a live attenuated strain of JUNV that is licensed only 45 in Argentina and ineffective against LASV or LCMV. On the other hand, current arenavirus 46 antiviral drug therapy is restricted to the use of the nucleoside analogue ribavirin, which is 47 only partially effective and associated with significant side effects (9, 25, 26) . Therefore, it is 48 important to develop novel antiviral strategies to combat human pathogenic arenaviruses, a 49 task that would be facilitated by a detailed understanding of the molecular and cell biology 50 of arenaviruses. 51
Arenaviruses are enveloped viruses with a bi-segmented, negative strand (NS) RNA 52 genome and a life cycle restricted to the cell cytoplasm (6). Each RNA genome segment 53 uses an ambisense coding strategy to direct the expression of two gene products in 54 opposite orientation and separated by a non-coding intergenic region (IGR). The Large (L) 55 segment (L; 7.2 kb) encodes the L protein, an RNA-dependent RNA polymerase (RdRp), 56 and the small RING finger protein Z that is the counterpart of the matrix (M) protein found in 57 many enveloped NS RNA viruses. The small (S) segment (S; 3.5 kb) encodes the viral 58 nucleoprotein (NP) and the glycoprotein precursor (GPC) that is post-translationally 59 processed to yield the peripheral virion attachment protein GP1 and the fusion-active 60 transmembrane protein GP2. Trimers of GP1/GP2 form the spikes that decorate the virus 61 surface and mediate cell entry via receptor-mediated endocytosis (6). 62
Many viruses interfere with signaling pathways in their infected host cells to favor an 63 environment conducive of a productive infection, which can also impact the host physiology 64 and contribute to virus associated pathogenesis and disease. Therefore the identification 65 and targeting of host cell factors and pathways involved in different steps of a virus life 66 cycle may uncover novel antiviral strategies. In this regard, the PI3K /Akt pathway, known 67 to regulate a variety of cellular processes including cell growth, proliferation, survival, and 68 metabolism (14), has also been involved in the regulation of cell entry (34), as well as RNA 69 replication and gene expression (38) for a variety of viruses. Thus, infection with the New 70
World (NW) arenavirus JUNV was shown to activate the PI3K/Akt pathway (20) , and 71 inhibition of the PI3K/Akt pathway resulted in decreased production of infectious progeny 72 due to a blockage on the recycling of the transferrin receptor involved in JUNV cell entry 73 (20). Because significant biological differences have been observed among different 74 arenaviruses (17), we examined whether the PI3K/Akt pathway played also a role in the life 75 cycle of LCMV, the prototypic Old World (OW) arenavirus, a group that includes LASV, the 76 HF arenavirus with the highest impact in public health. For this, we tested a variety of 77 commercially available PI3K/Akt inhibitors. The PI3K/Akt signaling pathway is initiated by 78 receptor-mediated recruitment of catalytically active PI3K to the membrane. Active PI3K 79 converts phosphatidylinositol 4, 5-biphosphate to phosphatidylinositol 3, 4, 5-triphosphate 80 (PIP3). PIP3 facilitates co-localization of Akt with its activating kinase PDK1 that mediates 81 phosphorylation of Akt at residue Thr 308 (T308) resulting in the initial activation of Akt that 82 is subsequent fully activated by a second phosphorylation event at Ser 473 (S473). 83
Consistent with previous findings treatment with the PI3K inhibitor LY294002 (LY) resulted 84 in strong inhibition of Akt phosphorylation (S473) that was associated with a robust 85 inhibitory effect on LCMV multiplication in the absence of cell toxicity. Mechanism of action 86 studies indicated that LY did not affect virus cell entry but rather viral budding and to lesser 87 extent viral RNA synthesis. To our knowledge, this is the first report showing a contribution 88 of the PI3K/Akt pathway to virus budding. The PI3K/Akt pathway is often upregulated in 89 tumors and therefore is being pursued as a target for anti-tumor therapy, and several 90 inhibitors of the PI3K/Akt pathway are currently undergoing clinical trials as potential drugs 91 for treating several different tumors (21). Our finding that BEZ-235, a dual PI3K/mTOR 92 inhibitor currently in cancer clinical trials, inhibited multiplication of LCMV in cultured cells, 93 provided further impetus to explore targeting of the PI3K/Akt pathway as a novel antiviral 94 strategy to combat human pathogenic arenaviruses. 95
96

MATERIALS AND METHODS 97
Plasmids 98 LCMV-and LASV-Z expressing plasmids have been described (40). These Z constructs 99
were Flag tagged at their C-termini. p-T7, pMG-CAT, pCAGGS-NP, and pCAGGS-L have 100 been described (18, 19) . 101
Chemical Inhibitors 102
Akt-IV and Akt-VIII were purchased from CALBIOCHEM (#124015 and #124018, 103 respectively). LY294002 was purchased from Cell signaling (#9901). BEZ-235 was 104 purchased from Selleck chemicals (#s1009). Rapamycin was purchased from SIGMA-105
ALDRICH (# R0395). 106
Cells and Viruses 107
293T cells were grown in Dulbecco's modified Eagle's medium (DMEM; Invitrogen) 108 containing 10% fetal bovine serum, 2mM l-glutamine, 100mg/ml streptomycin, and 100 109 U/ml penicillin. Recombinant LCMV (rLCMV), Armstrong strain, r3LCMV/GFP as well as 110 rVSV∆G-GFP/VSV-G and rVSV∆G-GFP/LCMV-GP have been described (12, 41) . The GP 111 expressed by rVSV∆G-GFP/LCMV-GP corresponded to that of Armstrong strain of LCMV. 112
Virus titration 113
LCMV titers were determined using an immunofocus assay (4). Briefly, 10-fold serial virus 114 dilutions were used to infect Vero cell monolayers in a 96-well plate, and at 20 h p.i., cells 115
were fixed with 4% paraformaldehyde (PFA) in PBS. After cell permeabilization by 116 treatment with 0.3% Triton X-100 in PBS containing 3% BSA, cells were stained by using 117 Samples were analyzed by Western Blot (WB) to detect either total or phosphorylated 126 (S473) Akt. 127
Cytotoxicity assay 128
The effect of compounds tested in 293T cell viability was assessed using the CellTiter-Glo 129 transfected with p-T7, pMG-CAT, pCAGGS-NP, and pCAGGS-L using conditions 149 previously described (18, 19, 29, 31, 32) . At 5 h post-transfection, the transfection medium 150 was replaced with fresh medium containing the indicated compounds and concentrations. 151
At 24 h post-transfection cell lysates were prepared to determine levels of CAT protein by 152 ELISA using a CAT ELISA kit (Roche, 11363727001). Briefly, cells were lysed with 1 ml of 153 lysis buffer and equal amounts (4 µl) of each sample used for ELISA. Dilutions of a known 154 amount of CAT were used to generate a calibration curve. CAT ELISA plates were 155 incubated for 1 h at 37 °C, followed by two washes with wash buffer, followed by reaction 156 with an antibody to CAT for 1 h at 37 °C. After reaction with the primary antibody, samples 157 were washed twice and then reacted with the secondary antibody conjugated to peroxidase 158 for 1 h at 37 °C, followed by two washes prior adding the substrate. After 20 min at room 159 temperature samples were analyzed using an ELISA reader (SPECTRA max plus 384, 160 Molecular Devices) to determine the absorbance (405 nm for samples, 490 nm for the 161 reference). 162
RNA analysis by Northern blot hybridization 163
Total cellular RNA was isolated by using TRI Reagent (Molecular Research Center, Inc) 164 according to the manufacturer's instructions and analyzed by Northern blot hybridization. 165
Briefly, RNA samples were fractionated by 2.2 M formaldehyde-agarose (1.2 %) gel 166 electrophoresis followed by transfer (4 h) in 20 X SSC of the RNA to a Magnagraph (0.22 167 µm) membrane using the rapid downward transfer system (TurboBlotter). Membrane bound 168 RNA was crosslinked by exposure to UV and the membrane was hybridize to a at the indicated concentrations (Fig 1A) . At the indicated h p.i. we determined titers of 206
infectious virus in tissue culture supernatants (TCS). The PI3K inhibitor LY inhibited LCMV 207
propagation following infection at both low and high moi, but the drug's inhibitory effect was 208 significantly stronger in cells infected at low moi (Fig 1A) . 209
In contrast to the results observed with LY, the Akt inhibitors Akt-IV and Akt-VIII did not 210 affect significantly LCMV propagation following infection at either low or high moi. This 211 finding led us to examine whether under our experimental conditions there was a 212 correlation between the antiviral activity of the compound tested and their ability to inhibit 213 Akt phosphorylation. For this, we treated 293T cells with the different inhibitors at the 214 indicated concentrations and 4 or 24 h later prepared cell lysates to determine levels of Akt 215 phosphorylation by Western blot (Fig 1Bi) . Contrary to the commonly assumed properties 216 of Akt-IV (16, 38), but consistent with a recent report (11), we observed that in 293T cells 217
Akt-IV did not inhibit Akt phosphorylation at residue S473. Unexpectedly, under our 218 experimental conditions Akt-VIII treatment also failed to inhibit Akt phosphorylation. In 219 contrast, LY treatment inhibited efficiently phosphorylation of Akt. At the concentrations 220 tested LY and Akt-VIII did not cause significant cell toxicity, whereas treatment with Akt-IV 221 even at the lowest (0.5 µM) concentration tested reduced cell survival by about 60 % as 222 determined by the Cell titer Glo assay (8) (Fig 1Bii) . 223
Our finding that LY inhibited very efficiently LCMV multiplication led us to explore the 224 possible repurposing of PI3K inhibitors as anti-arenaviral drugs. For this we used 225 which is currently in clinical trial for treatment of advanced solid tumors (21). BEZ-235 is a 226 synthetic low molecular mass compound belonging to the class of imidazoquinolines that 227 potently and reversibly inhibits class 1 PI3K catalytic activity by competing at its ATP-228 binding site. BEZ-235 also inhibits mTOR catalytic activity but does not target other protein 229 kinases (22, 36). Under our experimental conditions BEZ-235 inhibited in a dose-and 230 temporal-dependent manner Akt phosphorylation in 293T cells (Fig 2A) . Treatment with 1 231 nM BEZ-235 for 24 h resulted in significant reduced levels of phosphorylated Akt at S473, 232 whereas at 50 nM the inhibitory effect was already observed after 4 h treatment. Within the 233 dose range tested BEZ-235 exhibited minimal cell toxicity (Fig 2B) . To examine the 234 potential antiviral activity of BEZ-235 against LCMV, we infected 293T cells (moi = 0.01) 235
and treated them with BEZ-235 at the indicated concentrations, and at the indicated h p.i. 236
we determined titers of infectious virus in TCS (Fig 3) . Within the 0.5-5 µM range BEZ-235 237 caused about 2-2.5 logs reduction in production of infectious progeny in the absence of 238 noticeable cell toxicity. 239
Effect of PI3K inhibitors on LCMV entry 240
To examine the effect of LY and BEZ-235 on LCMV GP-mediated cell entry we used a 241 recombinant VSV (rVSV∆G-GFP/LCMV-GP) whose cell entry is mediated by the GP of 242 strain Armstrong of LCMV (41). The rational for using this rVSV was that multiplication of 243 VSV was shown not to be affected by LY (10). Therefore, an effect of LY or BEZ-235 244 treatment on rVSV∆G-GFP/LCMV-GP multiplication would reflect the drug's effect on 245 LCMV GP-mediated cell entry. We treated 293T cells with LY (50 µM) or BEZ-235 (5µM) 246 for 1 h prior infection (moi = 1) with rVSV∆G-GFP/LCMV-GP or with the control rVSV∆G-247 GFP/VSV-G, a rVSV expressing its own glycoprotein (G). At 12 h p.i. cells were fixed and 248 numbers of infected cells determined based on GFP positive cells. Neither LY (Fig 4A) nor 249 BEZ-235 (Fig 4B) suggest that an early step of cell entry was unlikely to be affected by LY or BEZ-235. 257
Effect of PI3K and Akt inhibitors on LCMV RNA replication and gene 258 transcription 259
To examine whether the PI3K/Akt pathway played a role in LCMV RNA replication and 260 gene transcription we used an LCMV minigenome (MG) assay (18, 19, 29, 31, 32) that 261 allowed us to separate the steps involved in virus RNA replication and transcription from 262 those involved in cell entry, as well as virus particle assembly and cell egress. In this MG-263 based assay expression of the CAT reporter gene was used as a surrogate to measure 264 levels of RNA synthesis by the intracellularly reconstituted LCMV polymerase complex. LY 265 exhibited a dose-dependent inhibitory effect on LCMV MG derived reporter gene 266 expression (30 % and 70 % reduction in CAT expression at 20 µM and 50 µM, respectively), 267 whereas treatment with Akt-VIII had a very modest effect on MG derived CAT expression 268 (Fig 5A) . Intriguingly, although Akt-IV did not exhibit an inhibitory effect on LCMV 269
propagation, treatment with Akt-IV resulted in a significant (40%) reduction of CAT 270 expression (Fig 5A) . A plausible explanation for these apparent contradicting findings 271 would be that Akt-IV treatment could have negatively impacted Pol-II based transcription 272 and thereby affecting levels of plasmid supplied LCMV NP and L proteins in the MG-based 273 assay. To evaluate this possibility we determined the effect of LY, Akt-VIII and Akt-IV on 274 firefly luciferase (Fluc) expression mediated by a Pol-II based expression plasmid (Fig 5B) . 275 LY (20 and 50 µM) and Akt-VIII (2.0 µM) did not affect significantly levels of Fluc 276 expression, whereas treatment with Akt-IV caused a very significant reduction in levels of 277
Fluc expression (50% at 0.5 µM). As with LY, we observed a dose-dependent inhibitory 278 effect of BEZ-235 on MG derived CAT expression (30%, 50%, and 65% reduction, at 50 279 nM, 500 nM and 5 µM, respectively) (Fig 5A) . BEZ-235 had a minimal effect on Pol-II 280 mediated expression of Fluc (Fig 5B) , suggesting that the effect of BEZ-235 on LCMV MG 281 expression was not the result of an overall drug's effect on Pol-II mediated transcription. 282
To further examine the effects of LY and BEZ-235 in RNA synthesis mediated by the 283 LCMV polymerase, we used Northern blot to determine levels of both RNA replication and 284 transcription in the LCMV MG assay (Fig 6) . We observed a good correlation between the 285 effect on CAT protein expression caused by either LY or BEZ-235 and the corresponding 286 drug effect on levels of both MG replication and MG-derived CAT mRNA. 287
Effect of LY and BEZ-235 on LCMV and LASV Z-mediated budding 288
Arenavirus Z protein has been shown to be the main driving force of virus budding (28, 289 37, 39). Since the magnitude of the inhibitory effect exerted by LY or BEZ-235 on LCMV 290 multiplication was much higher than their corresponding effects on viral RNA synthesis, we 291 examined whether LY could inhibit Z-mediated budding, a key step of the virus life cycle 292 required for production and propagation of infectious progeny. For this, we transfected 293
293T cells with either pC-LCMV-Z-FLAG or pC-LASV-Z-FLAG and 12 h later, cells were 294
washed and fresh media containing the indicated concentration of LY or BEZ-235 added. 295
At 24 h post treatment, we collected TCS and prepared cell lysates to detect levels of Flag-296 tagged Z protein in both cell lysates and VLP recovered from TCS of transfected cells by 297 WB using an anti-FLAG antibody. Both LY (Fig 7A) and BEZ-235 (Fig 7B) exerted a  298 robust dose-dependent inhibitory effect on Z mediated budding without significantly 299 affecting levels of Z expression in transfected cells. The reasons for the apparent higher 300 inhibitory effect of LY on budding mediated by LASV-Z, compared to LCMV-Z, remain to be 301
determined. 302
Effect of rapamycin on LCMV multiplication 303
BEZ-235 was shown to inhibit class 1 PI3K catalytic activity of both class 1 PI3K and 304 mTOR (22, 36). To assess the possible contribution of mTOR inhibition to the antiviral 305 activity associated with BEZ-235 we examined the effect of rapamycin (Rpm), a well 306
characterized mTOR inhibitor, on LCMV multiplication. Production of infectious virus in 307
Rpm-treated cells was not significantly affected (Fig 8A) . Consistent with this observation, 308 virus cell propagation (Fig 8B) and virus RNA replication and gene transcription (Fig 8C)  309 were not significantly affected by Rpm treatment. we investigated whether the PI3K/Akt pathway had also an effect on multiplication of the 334 prototypic OW arenavirus LCMV. 335
The PI3K inhibitor LY, but not the Akt inhibitors Akt-IV and Akt-VIII, inhibited 336 multiplication of LCMV following infection at low moi (Fig 1A) . Akt-VIII has IC50 of 58 nM, 337 210 nM and 2.12 µM for the Akt isoforms 1, 2 and 3, respectively. Therefore, in cell treated 338 with 2 µM Akt-VIII, Akt3 would be predicted to retain significant activity that could have 339 accounted for the lack of inhibition of LCMV multiplication in cells treated with 2 μM Akt-VIII. 340
Nevertheless, we observed that levels of p27 phosphorylation, known to be mainly an Akt3 341 target (5) were not affected in 293T cells treated with 2 µM Akt-VIII as determined by 342
Western blot using a phospho-p27 (T157)-specific antibody (not shown). In addition, 343 whereas LY treatment inhibited phosphorylation of Akt at S473 (Fig 1B) , under our 344 experimental conditions Akt phosphorylation at S473 was not significantly affected by 345 treatment with Akt-IV or Akt-VIII (Fig 1B) . The inability of Akt-IV to inhibit Akt 346 phosphorylation was unexpected based on its published properties (38), but consistent with 347 a recent report showing that Akt-IV blocked VSV multiplication without affecting Akt 348 phosphorylation (11). Akt-VIII has been shown to be a direct inhibitor of the kinase activity 349
of Akt in several cell systems (2) and to have antiviral activity (1). The reason why under 350 our experimental conditions we did not observe an Akt-VIII mediated inhibition of Akt 351 phosphorylation is presently unknown. One possibility is that the inhibitory activity of Akt-352 VIII may be cell dependent and at 2 µM it could robustly inhibit phosphorylation of Akt in 353 BHK-21 (11) but not in 293T cells used in our studies. 354
355
The lesser inhibitory effect of LY on LCMV multiplication following infection at high 356 compared to low moi suggested a more strict requirement of the integrity of the PI3K/Akt 357 pathway in the late steps of the virus life cycle. Accordingly, LY and BEZ-235 treatment did 358 not affect cell entry mediated by the GP of Armstrong strain of LCMV (Fig 4) . However, a 359 recent report by Pasqual and colleagues has documented that LASV and LCMV enter host 360 cells via the mutlivesicular body (MVB) pathway (27), and biogenesis and functionality of 361 the MVB requires the lipid PI3P and hence also PI3K activity. Accordingly, treatment with 362 the PI3K inhibitor wortmannin significantly affected cell entry by LASV or LCMV GP (27). A 363 possible explanation for these apparent conflicting findings is that wortmannin is able to 364 rapidly and specifically inhibit some of the non-classical PI3K isoforms that might 365 compensate for LY-mediated inhibition of major PI3K forms. Likewise, differences in cell 366 entry mediated by GPs of Armstrong (our study) and Cl-13 (study by Pasqual and 367 colleagues) strains of LCMV may have also contributed to the differences between our 368 results and those reported by Pasqual and colleague (27) . In this regard it should be noted 369 that VSV cell entry was shown to be depended also on the MVB and ESCRT but it was not 370 affected by wortmannin treatment, suggesting that VSV-G mediated fusion with 371 membranes of the intraluminal vesicles (ILV) within the MVB takes place under mildly 372 acidic pH and the virus ribonucleoprotein core is delivered to late endosomes in the lumen 373 of the ILVs (23). Similarly, it is plausible that Armstrong GP2 may promote fusion between 374 viral and cellular membranes at higher pH than GP2 from Cl-13 or LASV. 375
Both LY and BEZ-235 had a significant and specific inhibitory effect on MG-derived 376 CAT expression levels (Fig 5A) . In contrast, the observed inhibitory effect of Akt-IV on MG-377 derived reporter gene activity was likely a reflection of a general effect of Akt-IV on cell 378 viability and Pol-II mediated transcription (Fig 1Bii and 5B) . These results suggested a role 379 the PI3K/Akt pathway in LCMV RNA replication and gene transcription, which was 380 experimentally supported by Northern blot analysis of MG-derived RNA species in the 381 absence or presence of PI3K inhibitors (Fig 6) . The mechanisms by which either LY or 382 BEZ-235 affect the activity of the arenavirus polymerase remain to be elucidated. Previous 383 studies have shown that Akt directly phosphorylates Parainfluenza virus 5 (PIV5) and 384
Respiratory syncytial virus (RSV) polymerase cofactor P protein, and this phosphorylation 385 of P has a critical role for virus polymerase activity (38). However, arenaviruses do not 386 have a counterpart of the P protein found in many other NS RNA viruses. 387
Consistent with a more pronounced involvement of the PI3K/Akt pathway in late steps 388 of the LCMV life cycle, both LY (Fig 7A) and BEZ-235 (Fig 7B) exhibited a strong dose-389 dependent inhibitory effect on Z mediated budding, which documents for the first time a role 390 of the PI3K/Akt pathway in virus budding. The degree of inhibition of Z-mediated budding 391 appeared to be higher in cells treated with BEZ-235 compared to LY-treated cells. It seems 392 however unlikely that a PI3K-independent mTOR activation may have also contributed to Z-393 mediated budding, as the mTOR inhibitor Rpm did not affect significantly LCMV 394 multiplication in cultured cells (Fig 8) . The PI3K/Akt pathway participates in the regulation 395 of many cellular processes including vesicular trafficking (35). PI3P, the product of the PI3K 396 activity, is needed for efficient assembly of the ESCRT complex at the limiting membrane of 397 the early endosome and some ESCRT proteins contain modules that recognize PI3P. 398
Budding of a variety of enveloped viruses, including arenaviruses, involves interactions 399 between viral budding proteins and ESCRT. It is plausible that these interactions may be 400 facilitated by virus induced PI3P-rich "microdomains" at the site of budding and thereby 401 inhibition of PI3K activity will disrupt normal budding. The PI3K/Akt pathway might be 402 BEZ-235 (B), and 24 h later TCS were collected and total cell lysates prepared. VLPs were 624 isolated from TCS as described (40). Levels of Z protein in total cell lysates and VLPs were 625 detected by WB using an antibody to FLAG (Cayman, 162150) . 626 
